Bicalutamide
6 NDCs across 4 manufacturers|6 Generic,0 Brand
Bicalutamide is used to treat prostatic neoplasms, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Oct 4, 1995, and the first generic was approved Jul 6, 2009. FDA's Orange Book lists 7 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $7 million on Bicalutamide across 210,000 claims for 74,000 beneficiaries.
Bicalutamide is available as 6 NDCs from 4 manufacturers (6 generic, 0 brand), with NADAC prices from $0.40 to $0.43 per EA — a 7% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
6G / 0B
Manufacturers
4
competing in market
Price Spread
$0.40 – $0.43
per EA
7d Activity
avg -2.9% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Accord Healthcare Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Androgen Receptor Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
4 manufacturers producing BICALUTAMIDE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
BICALUTAMIDE 50 MG TABLET | $0.4300 per EA | — |
BICALUTAMIDE 50 MG TABLET | $0.4044 per EA | -2.86% |
BICALUTAMIDE 50 MG TABLET | $0.4044 per EA | -2.86% |
BICALUTAMIDE 50 MG TABLET | $0.4044 per EA | -2.86% |
BICALUTAMIDE 50 MG TABLET | $0.4044 per EA | -2.86% |
BICALUTAMIDE 50 MG TABLET | $0.4028 per EA | — |
Frequently Asked Questions
What is Bicalutamide used to treat?
Bicalutamide is used to treat prostatic neoplasms, per the National Library of Medicine's MED-RT classification.
When did Bicalutamide become available as a generic?
FDA approved the first generic Bicalutamide (ANDA) on Jul 6, 2009. The Orange Book currently lists 7 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Bicalutamide?
In 2024, Medicare Part D spent $7 million on Bicalutamide across 210,000 claims for 74,000 beneficiaries.
How many Bicalutamide products are on the market?
The Bicalutamide drug market contains 6 NDCs from 4 manufacturers — 6 generic and 0 brand products.
What is the price range for Bicalutamide?
NADAC reference prices for Bicalutamide range from $0.4028 to $0.4300 per EA — a 7% difference between cheapest and most expensive.
Which manufacturers make Bicalutamide?
4 manufacturers list Bicalutamide in NADAC. Ranked by number of NDCs, the largest are Accord Healthcare Inc. (2), Sun Pharmaceutical Industries Inc. (2), ANI Pharmaceuticals, Inc. (1), Major Pharmaceuticals (1).
How has the price of Bicalutamide changed recently?
Over the past 7 days, 0 Bicalutamide NDCs rose and 4 fell, with a market-wide average change of -2.9%.